{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T00:20:13Z","timestamp":1794615613131,"version":"4.9.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Introduction<\/jats:title>\n<jats:p>Coronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2. Although most patients with COVID-19 develop asymptomatic or mild disease, some patients develop severe disease. The effectiveness of various therapeutic agents, including antiviral drugs, steroids, and anti-inflammatories for COVID-19, have been being confirmed. The effect of administering steroids in early disease is unclear. This study therefore aimed to evaluate the effectiveness and risk of exacerbation of steroids administered preceding antiviral drugs in patients with COVID-19 pneumonia.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective, single-center, observational study included consecutive patients with COVID-19 between March 2020 and March 2021. Patients were divided into a steroids-first group and antiviral-drugs-first group. Mortality, duration of hospitalization, incidence rate and duration of intensive care unit (ICU) admission, intubation, and extracorporeal membrane oxygenation (ECMO) induction of the two groups were compared.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 258 patients were admitted during the study period. After excluding patients who received symptomatic treatment only, who were taking immunosuppressive drugs, or who were administered antiviral drugs only, 68 patients were included in the analysis, 16 in the steroids-first group and 52 in the antiviral-drugs-first group. The rate of intubation, ICU admission and ECMO induction were significantly higher in the steroids-first group than in the antiviral-drugs-first group (81.3% vs. 33.3, <jats:italic>p<\/jats:italic>&lt;0.001, 75.0% vs. 29.4%, <jats:italic>p<\/jats:italic> = 0.001, and 31.3% vs. 7.8%, <jats:italic>p<\/jats:italic> = 0.017, respectively). Furthermore, patients who received steroids within ten days after starting antiviral drugs had significantly lower rates of ICU admission, intubation, and ECMO induction. (81.3% vs. 42.9% <jats:italic>p<\/jats:italic> = 0.011, 75.0% vs. 37.1% <jats:italic>p<\/jats:italic> = 0.012, and 31.3% vs. 8.6% <jats:italic>p<\/jats:italic> = 0.039, respectively).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Administering steroids prior to antiviral drugs soon after symptom onset can aggravate disease severity. When administration of steroids is considered soon after symptom onset, it may be safer to initiate antiviral drugs first.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0256977","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T17:45:34Z","timestamp":1630604734000},"page":"e0256977","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: A retrospective study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6706-5595","authenticated-orcid":true,"given":"Yu","family":"Shionoya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshibumi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6759-2026","authenticated-orcid":true,"given":"Hajime","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8781-2367","authenticated-orcid":true,"given":"Kohei","family":"Shikano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Takayanagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misuzu","family":"Yahaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taka-aki","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Igari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Sakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuji","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"pone.0256977.ref001","unstructured":"World Health Organization. Coronavirus disease (COVID-19) pandemic (2020). 2020 [cited 2021 04\/03]. Available from: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019."},{"issue":"13","key":"pone.0256977.ref002","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1001\/jama.2020.2648","article-title":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention","volume":"323","author":"Z Wu","year":"2020","journal-title":"JAMA"},{"issue":"8","key":"pone.0256977.ref003","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"RC Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"10285","key":"pone.0256977.ref004","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"O Abani","year":"2021","journal-title":"The Lancet"},{"issue":"5","key":"pone.0256977.ref005","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal","volume":"39","author":"HK Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant"},{"issue":"18","key":"pone.0256977.ref006","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40265-020-01421-w","article-title":"Immune Therapy, or Antiviral Therapy, or Both for COVID-19: A Systematic Review","volume":"80","author":"F Cantini","year":"2020","journal-title":"Drugs"},{"key":"pone.0256977.ref007","unstructured":"Ministry of Health and Welfare. Guide to the Treatment of Novel Coronavirus Infections (COVID-19), Version 4.1. 2020 [cited 2021 04\/03]. Available from: https:\/\/www.mhlw.go.jp\/content\/000712473.pdf."},{"key":"pone.0256977.ref008","unstructured":"Prevention CfDCa. People with Certain Medical Conditions 2021 [updated March 29th 2021]. Available from: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html."},{"key":"pone.0256977.ref009","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cegh.2020.07.006","article-title":"Antivirals for COVID-19: A critical review","volume":"9","author":"A Frediansyah","year":"2021","journal-title":"Clinical epidemiology and global health."},{"issue":"19","key":"pone.0256977.ref010","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"pone.0256977.ref011","unstructured":"National Institutes of Health. Therapeutic Management of Hospitalized Adults With COVID-19. [cited 2021 07\/25]. Available from: https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management\/hospitalized-adults\u2014therapeutic-management\/."},{"issue":"7","key":"pone.0256977.ref012","doi-asserted-by":"crossref","first-page":"e2114741","DOI":"10.1001\/jamanetworkopen.2021.14741","article-title":"Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19","volume":"4","author":"ME Ohl","year":"2021","journal-title":"JAMA network open"},{"issue":"6","key":"pone.0256977.ref013","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19\u2014Interim WHO Solidarity Trial Results","volume":"384","author":"H Pan","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0256977.ref014","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","article-title":"Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome","volume":"197","author":"YM Arabi","year":"2018","journal-title":"American journal of respiratory and critical care medicine"},{"issue":"4","key":"pone.0256977.ref015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jcv.2004.07.006","article-title":"Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients","volume":"31","author":"N Lee","year":"2004","journal-title":"Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology"},{"issue":"7","key":"pone.0256977.ref016","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/cid\/ciaa832","article-title":"Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With COVID-19. Clinical infectious diseases: an official publication of the","volume":"72","author":"Y Chen","year":"2021","journal-title":"Infectious Diseases Society of America"},{"issue":"4","key":"pone.0256977.ref017","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s40121-020-00337-y","article-title":"Effect of Corticosteroid Therapy on the Duration of SARS-CoV-2 Clearance in Patients with Mild COVID-19: A Retrospective Cohort Study","volume":"9","author":"C Ding","year":"2020","journal-title":"Infectious diseases and therapy"},{"issue":"7","key":"pone.0256977.ref018","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciaa829","article-title":"High-dose but Not Low-dose Corticosteroids Potentially Delay Viral Shedding of Patients With COVID-19","volume":"72","author":"S Li","year":"2021","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"1","key":"pone.0256977.ref019","doi-asserted-by":"crossref","first-page":"13689","DOI":"10.1038\/s41598-020-70387-2","article-title":"Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019","volume":"10","author":"F Liu","year":"2020","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0256977.ref020","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1172\/JCI140617","article-title":"Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome","volume":"130","author":"J Liu","year":"2020","journal-title":"The Journal of clinical investigation"},{"issue":"1","key":"pone.0256977.ref021","doi-asserted-by":"crossref","first-page":"21291","DOI":"10.1038\/s41598-020-78039-1","article-title":"Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19","volume":"10","author":"V Spagnuolo","year":"2020","journal-title":"Sci Rep."},{"issue":"1","key":"pone.0256977.ref022","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/22221751.2020.1732837","article-title":"Detectable 2019-nCoV viral RNA in blood is a strong indicator for the further clinical severity","volume":"9","author":"W Chen","year":"2020","journal-title":"Emerging microbes & infections"},{"issue":"10","key":"pone.0256977.ref023","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.1172\/JCI138759","article-title":"Kinetics of viral load and antibody response in relation to COVID-19 severity","volume":"130","author":"Y Wang","year":"2020","journal-title":"The Journal of clinical investigation"},{"issue":"7","key":"pone.0256977.ref024","doi-asserted-by":"crossref","first-page":"e524","DOI":"10.1016\/S2352-3026(21)00105-8","article-title":"COVID-19-associated coagulopathy and antithrombotic agents-lessons after 1 year","volume":"8","author":"J Leentjens","year":"2021","journal-title":"The Lancet Haematology"},{"issue":"6","key":"pone.0256977.ref025","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19","volume":"7","author":"M Levi","year":"2020","journal-title":"The Lancet Haematology"},{"issue":"4","key":"pone.0256977.ref026","first-page":"844","article-title":"Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis","volume":"18","author":"N Tang","year":"2020","journal-title":"JTH"},{"issue":"1","key":"pone.0256977.ref027","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1016\/S2213-2600(20)30530-0","article-title":"Corticosteroids for COVID-19: the search for an optimum duration of therapy","volume":"9","author":"GP Mishra","year":"2021","journal-title":"The Lancet Respiratory medicine"},{"issue":"2","key":"pone.0256977.ref028","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/j.jvca.2020.11.057","article-title":"Corticosteroids for Patients With Coronavirus Disease 2019 (COVID-19) With Different Disease Severity: A Meta-Analysis of Randomized Clinical Trials","volume":"35","author":"L Pasin","year":"2021","journal-title":"Journal of cardiothoracic and vascular anesthesia"},{"issue":"5","key":"pone.0256977.ref029","doi-asserted-by":"crossref","first-page":"e0252057","DOI":"10.1371\/journal.pone.0252057","article-title":"Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia","volume":"16","author":"MA Pinz\u00f3n","year":"2021","journal-title":"PloS one"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256977","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T17:45:59Z","timestamp":1630604759000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0256977"}},"subtitle":[],"editor":[{"given":"Aleksandar R.","family":"Zivkovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0256977","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.g001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.g002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.t001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.t002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s004","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s005","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s006","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s007","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s008","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s009","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.s010","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.r001","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.r002","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.r003","asserted-by":"subject"},{"id-type":"doi","id":"https:\/\/doi.org\/10.1371\/journal.pone.0256977.r004","asserted-by":"subject"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]}}}